Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab in muscle wasting after hip fracture surgery
NCT02152761Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab in muscle atrophy (4 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Total Lean Body Mass Measured by DXA at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
bimagrumab
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on NCT02152761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152761.